专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2009046407A3 B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS 审中-公开
标题翻译： B7家族成员zB7H6及相关组合物和方法
公开(公告)号：WO2009046407A3
公开(公告)日：2011-05-19
申请号：PCT/US2008078911
申请日：2008-10-06
申请人： ZYMOGENETICS INC , BRANDT CAMERON S , KENNEDY JACOB J , XU WENFENG , YI EUGENE C , FOX BRIAN A , GAO ZEREN , SIVAKUMAR PALLAVUR V
发明人： BRANDT CAMERON S , KENNEDY JACOB J , XU WENFENG , YI EUGENE C , FOX BRIAN A , GAO ZEREN , SIVAKUMAR PALLAVUR V
IPC分类号： A61K39/395 , C07K16/28
CPC分类号： C07K16/2827 , A61K47/6851 , A61K2039/505 , C07K14/70532 , C07K2317/21 , C07K2317/24 , C07K2317/30 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2319/30 , G01N33/5011 , G01N2333/705 , G01N2500/02
摘要： Disclosed is a newly identified B7 family member, zB7H6, which functions as a counter-receptor for the NK cell triggering receptor, NKp30. Methods and compositions for modulating NKp30-mediated NK cell activity based on the interaction of zB7H6 with NKp30, as well as related screening methods, are also disclosed. Further disclosed are anti-zB7H6 antibodies as well as antibody-drug conjugates comprising an anti-zB7H6 antibody conjugated to a therapeutic agent, including methods for using such antibodies and antibody-drug conjugates to exert therapeutic effects against zB7H6-expressing cells.
摘要翻译：公开了一种新鉴定的B7家族成员，zB7H6，其作为NK细胞触发受体NKp30的反受体。还公开了基于zB7H6与NKp30的相互作用调节NKp30介导的NK细胞活性的方法和组合物以及相关筛选方法。还公开了抗zB7H6抗体以及包含与治疗剂缀合的抗-zB7H6抗体的抗体 - 药物偶联物，包括使用这种抗体和抗体 - 药物偶联物对表达zB7H6的细胞施加治疗效果的方法。

2. 发明申请

WO2009120922A2 COMPOSITIONS AND METHODS FOR INHIBITING PDGFRBETA AND VEGF-A 审中-公开
标题翻译：用于抑制PDGFRBETA和VEGF-A的组合物和方法
公开(公告)号：WO2009120922A2
公开(公告)日：2009-10-01
申请号：PCT/US2009038495
申请日：2009-03-27
申请人： ZYMOGENETICS INC , SIVAKUMAR PALLAVUR V , GILBERTSON DEBRA G , SNAVELY MARSHALL D , MABRY GEORGE R , YI EUGENE C , YAO YUE , PRESNELL SCOTT R
发明人： SIVAKUMAR PALLAVUR V , GILBERTSON DEBRA G , SNAVELY MARSHALL D , MABRY GEORGE R , YI EUGENE C , YAO YUE , PRESNELL SCOTT R
IPC分类号： A61K39/395 , A61P35/00 , C07K16/22 , C07K16/28
CPC分类号： C07K16/00 , A61K2039/505 , C07K16/22 , C07K16/2863 , C07K2317/21 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/90 , C07K2317/92
摘要： Disclosed are antagonists of PDGF receptor ß (PDGFRß) and VEGF-A, including neutralizing anti-PDGFRß and anti-VEGF-A antibodies, as well as related compositions and methods. Anti-PDGFRß and anti-VEGF-A antibodies disclosed herein include bispecific antibodies capable of binding and neutralizing both PDGFRß and VEGF-A. Also disclosed are methods of treating an neovascular disorder, such as cancer or an neovascular ocular disorder, using a PDGFRß and/or VEGF-A antagonist.
摘要翻译：公开了PDGF受体β（PDGFRβ）和VEGF-A的拮抗剂，包括中和抗PDGFRβ和抗VEGF-A抗体，以及相关的组合物和方法。本文公开的抗PDGFRβ和抗VEGF-A抗体包括能够结合和中和PDGFRβ和VEGF-A两者的双特异性抗体。还公开了使用PDGFRβ和/或VEGF-A拮抗剂治疗新生血管性疾病如癌症或新生血管性眼病的方法。

3. 发明申请

WO2005052001A3 ANTI-IL-20 RECEPTOR ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：抗IL-20受体抗体和结合合作伙伴及其使用方法
公开(公告)号：WO2005052001A3
公开(公告)日：2005-08-04
申请号：PCT/US2004039097
申请日：2004-11-19
申请人： ZYMOGENETICS INC , XU WENFENG , KINDSVOGEL WAYNE R , CHEN ZHI , HUGHES STEVEN D , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
发明人： XU WENFENG , KINDSVOGEL WAYNE R , CHEN ZHI , HUGHES STEVEN D , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K14/715 , C07K16/24 , C07K16/28 , C12P21/04
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 receptor polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 receptor antibodies and binding partners, including anti-IL-20RA, anti-IL-20RB and anti-IL-20RA/IL-20RB antibodies as well as methods for antagonizing IL-20RA and IL-20RB, either individually or together, using such antibodies and binding partners.
摘要翻译：本发明涉及阻断IL-20受体多肽分子的活性。 IL-20是涉及炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。本发明包括抗IL-20受体抗体和结合配偶体，包括抗IL-20RA，抗IL-20RB和抗IL-20RA / IL-20RB抗体以及拮抗IL-20RA和IL- 20RB，单独或一起使用这种抗体和结合配偶体。

4. 发明申请

WO2005052000A3 ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：抗IL-20抗体和结合的伙伴以及炎症中使用的方法
公开(公告)号：WO2005052000A3
公开(公告)日：2005-10-27
申请号：PCT/US2004039071
申请日：2004-11-19
申请人： ZYMOGENETICS INC , XU WENFENG , KINDSVOGEL WAYNE R , CHEN ZHI , HUGHES STEVEN D , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
发明人： XU WENFENG , KINDSVOGEL WAYNE R , CHEN ZHI , HUGHES STEVEN D , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
IPC分类号： A61K38/00 , A61K38/20 , C07K14/54 , C07K14/715 , C07K16/24 , C07K16/28 , C12P21/04
CPC分类号： C07K16/2866 , A61K38/1793 , A61K38/20 , A61K47/60 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/73 , C07K2317/76 , C07K2319/30
摘要： The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译：本发明涉及阻断IL-20多肽分子的活性。 IL-20是参与炎症过程和人类疾病的细胞因子。 IL-20RA / IL-20RB是IL-20的常见受体。本发明包括抗IL-20抗体和结合配偶体，以及使用此类抗体和结合配偶体来拮抗IL-20的方法。

5. 发明申请

WO2004085475A3 ANTI-IL-20 ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：抗IL-20抗体和结合合作伙伴及其在炎症中的使用方法
公开(公告)号：WO2004085475A3
公开(公告)日：2005-07-14
申请号：PCT/US2004008955
申请日：2004-03-24
申请人： ZYMOGENETICS INC , XU WENFENG , KINDSVOGEL WAYNE , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
发明人： XU WENFENG , KINDSVOGEL WAYNE , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
IPC分类号： C07K14/54 , C07K14/715 , C07K16/24 , C07K16/28 , A61P37/00
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-20 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. The present invention includes anti-IL-20 and anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.
摘要翻译：本发明涉及阻断，抑制，降低，拮抗或中和IL-20多肽分子的活性。 IL-20和IL-22是涉及炎症过程和人类疾病的细胞因子。本发明包括抗IL-20和抗IL-22RA抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-20的方法。

6. 发明申请

WO2004085476A3 ANTI-IL-22RA ANTIBODIES AND BINDING PARTNERS AND METHODS OF USING IN INFLAMMATION 审中-公开
标题翻译：抗IL-22RA抗体和结合合作伙伴及其在炎症中的使用方法
公开(公告)号：WO2004085476A3
公开(公告)日：2005-03-31
申请号：PCT/US2004008956
申请日：2004-03-24
申请人： ZYMOGENETICS INC , XU WENFENG , KINDSVOGEL WAYNE , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
发明人： XU WENFENG , KINDSVOGEL WAYNE , CHANDRASEKHER YASMIN A , DILLON STACEY R , LEHNER JOYCE M , SIADAK ANTHONY W , SIVAKUMAR PALLAVUR V , MOORE MARGARET D
IPC分类号： C07K14/54 , C07K14/715 , C07K16/24 , C07K16/28
CPC分类号： C07K16/2866 , A61K2039/505 , C07K14/54 , C07K14/7155 , C07K16/244 , C07K2317/34 , C07K2317/73 , C07K2319/00 , C07K2319/30
摘要： The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of IL-22, IL-20, or both IL-20 and IL-22 polypeptide molecules. IL-20 and IL-22 are cytokines that are involved in inflammatory processes and human disease. IL-22RA (zcytor11) is a common receptor for IL-20 and IL-22. The present invention includes anti-IL-22RA antibodies and binding partners, as well as methods for antagonizing IL-22 or both IL-20 and IL-22 using such antibodies and binding partners.
摘要翻译：本发明涉及阻断，抑制，减少，拮抗或中和IL-22，IL-20或IL-20和IL-22多肽分子的活性。 IL-20和IL-22是涉及炎症过程和人类疾病的细胞因子。 IL-22RA（zcytor11）是IL-20和IL-22的常见受体。本发明包括抗IL-22RA抗体和结合配偶体，以及使用这种抗体和结合配偶体拮抗IL-22或IL-20和IL-22两者的方法。

7. 发明申请

WO2005030196A3 METHODS OF TREATING AUTOIMMUNE DISEASES USING IL-21 审中-公开
标题翻译：使用IL-21治疗自身免疫性疾病的方法
公开(公告)号：WO2005030196A3
公开(公告)日：2005-09-29
申请号：PCT/US2004031710
申请日：2004-09-27
申请人： ZYMOGENETICS INC , SIVAKUMAR PALLAVUR V , NELSON ANDREW J
发明人： SIVAKUMAR PALLAVUR V , NELSON ANDREW J
IPC分类号： A61K38/20
CPC分类号： A61K38/20
摘要： Administration of IL-21 results in decreasing autoimmune responses and thereby provides a beneficial treatment for autoimmune diseases. Specific autoimmune diseases that may be treated include multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus, psoriasis, ankylosing spondilitis, scleroderma, Type I diabetes, psoriatic arthritis, osteoarthritis, inflammatory bowel disease, atopic dermatitis and asthma. Pharmaceutical compositions can include IL-21 polypeptides and active fragments thereof.
摘要翻译： IL-21的施用导致自身免疫反应降低，从而为自身免疫疾病提供有益的治疗。可以治疗的特异性自身免疫性疾病包括多发性硬化，类风湿性关节炎，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，I型糖尿病，牛皮癣关节炎，骨关节炎，炎症性肠病，特应性皮炎和哮喘。药物组合物可以包括IL-21多肽及其活性片段。

8. 发明申请

WO2007111714B1 IL-21 ANTAGONISTS 审中-公开
标题翻译： IL-21拮抗剂
公开(公告)号：WO2007111714B1
公开(公告)日：2008-05-02
申请号：PCT/US2006061277
申请日：2006-11-28
申请人： ZYMOGENETICS INC , SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
发明人： SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
IPC分类号： C07K16/24 , A61K39/00 , C07K14/54
CPC分类号： C07K16/244 , A61K39/3955 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.
摘要翻译：鉴定结合IL-21蛋白的单克隆抗体。这些抗体用于鉴定结合中和IL-21活性的IL-21蛋白的区域。描述了杂交瘤和产生抗IL-21单克隆抗体的方法。单克隆抗体可用于治疗IL-21介导的疾病，其可能包括自身免疫性和炎性疾病如胰腺炎，I型糖尿病（IDDM），格雷夫斯病，炎性肠病（IBD），克罗恩病，溃疡性结肠炎，肠易激综合征综合征，多发性硬化症，类风湿性关节炎，憩室病，系统性红斑狼疮，牛皮癣，强直性脊柱炎，硬皮病，系统性硬化症，银屑病关节炎，骨关节炎，特应性皮炎，白癜风，移植物抗宿主病（GVHD），皮肤T细胞淋巴瘤，干燥综合征，肾小球肾炎，IgA肾病，移植物宿主病，移植排斥反应，特应性皮炎，抗磷脂综合征，哮喘和其他自身免疫性疾病。

9. 发明申请

WO2006012644A3 USE OF IL-28 AND IL-29 TO TREAT CANCER 审中-公开
标题翻译：使用IL-28和IL-29治疗癌症
公开(公告)号：WO2006012644A3
公开(公告)日：2007-02-01
申请号：PCT/US2005026951
申请日：2005-07-29
申请人： ZYMOGENETICS INC , DOYLE SEAN , KLUCHER KEVIN M , SIVAKUMAR PALLAVUR V , KINDSVOGEL WAYNE R , CHAN CHUNG
发明人： DOYLE SEAN , KLUCHER KEVIN M , SIVAKUMAR PALLAVUR V , KINDSVOGEL WAYNE R , CHAN CHUNG
IPC分类号： A61K38/20 , A61P35/00 , C07K14/54
CPC分类号： A61K38/20 , A61K38/21 , A61K47/60 , C07K14/54 , C07K14/715 , C07K14/7155 , A61K2300/00
摘要： Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as a monotherapy or in combination with other known cancer and/or autoimmune therapeutics.
摘要翻译：使用IL-28和IL-29分子治疗患有癌症和自身免疫疾病的患者的方法。 IL-28和IL-29分子包括与人IL-28或IL-29多肽序列具有同源性的多肽，以及与具有IL-28和IL-29功能活性的多肽融合的蛋白质。分子可以用作单一疗法或与其它已知的癌症和/或自身免疫治疗剂组合使用。

10. 发明申请

WO2007114861A3 IL-21 RECEPTOR ANTAGONISTS 审中-公开
标题翻译： IL-21受体拮抗剂
公开(公告)号：WO2007114861A3
公开(公告)日：2008-05-22
申请号：PCT/US2006061285
申请日：2006-11-28
申请人： ZYMOGENETICS INC , SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
发明人： SIVAKUMAR PALLAVUR V , JASPERS STEPHEN R
IPC分类号： C07K16/28 , A61K39/395
CPC分类号： C07K16/2866 , A61K2039/505 , C07K16/244 , C07K2317/76 , C07K2319/30 , Y10S530/809
摘要： Monoclonal antibodies to the IL-21 receptor and multimeric complexes comprising the IL-21 receptor; including monoclonal antibodies to the heterodimeric receptor, IL-21/IL-2R ; have been prepared. The invention also describes a method of producing said antibodies. And, the invention also describes a method of treatment comprising using said antibodies to suppress an immune response.
摘要翻译： IL-21受体的单克隆抗体和包含IL-21受体的多聚复合物; 包括对异二聚体受体的单克隆抗体，IL-21 / IL-2R; 已经准备好了本发明还描述了产生所述抗体的方法。而且，本发明还描述了一种包括使用所述抗体抑制免疫应答的治疗方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式